Below are the most recent publications written about "Flutamide" by people in Profiles.
-
Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1504-1515.
-
Hoang DT, Gu L, Liao Z, Shen F, Talati PG, Koptyra M, Tan SH, Ellsworth E, Gupta S, Montie H, Dagvadorj A, Savolainen S, Leiby B, Mirtti T, Merry DE, Nevalainen MT. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Mol Cancer Ther. 2015 Mar; 14(3):713-26.
-
Pike JW, McDowell E, McCahan SM, Johnson KJ. Identification of gene expression changes in postnatal rat foreskin after in utero anti-androgen exposure. Reprod Toxicol. 2014 Aug; 47:42-50.
-
Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 2012 Sep 01; 118(17):4139-47.
-
Sheth SU, Palange D, Xu DZ, Wei D, Feketeova E, Lu Q, Reino DC, Qin X, Deitch EA. Testosterone depletion or blockade in male rats protects against trauma hemorrhagic shock-induced distant organ injury by limiting gut injury and subsequent production of biologically active mesenteric lymph. J Trauma. 2011 Dec; 71(6):1652-8.
-
Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003 Jan; 169(1):245-50.
-
Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol. 1998; 34 Suppl 3:18-23.
-
Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol. 1997 Aug; 15(8):2928-38.
-
Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am. 1997 May; 24(2):421-31.
-
Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst. 1997 Jan 15; 89(2):158-65.